HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoon S Cho-Chung Selected Research

Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)

9/2006Autoantibody cancer biomarker: extracellular protein kinase A.
11/2005Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
11/2005Tumor reversion: protein kinase A isozyme switching.
8/2005CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
12/2004Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors.
11/2004Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion.
7/2004Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
3/2004Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray.
3/2003Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
6/2002Dissecting the circuitry of protein kinase A and cAMP signaling in cancer genesis: antisense, microarray, gene overexpression, and transcription factor decoy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoon S Cho-Chung Research Topics

Disease

15Neoplasms (Cancer)
09/2006 - 02/2002
3Carcinogenesis
11/2005 - 07/2004
2Carcinoma (Carcinomatosis)
08/2005 - 03/2003
2Prostatic Neoplasms (Prostate Cancer)
03/2003 - 02/2002
1Disease Progression
09/2008
1Ovarian Neoplasms (Ovarian Cancer)
09/2008
1Osteoporosis
03/2006
1Breast Neoplasms (Breast Cancer)
07/2004

Drug/Important Bio-Agent (IBA)

11Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
09/2006 - 02/2002
4DNA (Deoxyribonucleic Acid)IBA
11/2005 - 11/2002
4Antisense OligonucleotidesIBA
11/2005 - 06/2002
3Biomarkers (Surrogate Marker)IBA
09/2008 - 06/2006
3Cyclic AMP (AMP, Cyclic)IBA
12/2004 - 02/2002
2AutoantibodiesIBA
09/2006 - 06/2006
2IsoenzymesIBA
11/2005 - 11/2004
2OligodeoxyribonucleotidesIBA
08/2005 - 02/2002
2Proteins (Proteins, Gene)FDA Link
08/2005 - 02/2002
2Complementary DNA (cDNA)IBA
03/2004 - 06/2002
2Nucleic AcidsIBA
03/2004 - 03/2003
2Transcription Factor AP-2IBA
12/2003 - 11/2002
2AndrogensIBA
03/2003 - 02/2002
1Conditioned Culture MediaIBA
09/2006
1AntigensIBA
09/2006
1Neoplasm Antigens (Tumor Antigens)IBA
06/2006
1Tumor Biomarkers (Tumor Markers)IBA
06/2006
1Estrogens (Estrogen)FDA Link
03/2006
19,10-Dimethyl-1,2-benzanthraceneIBA
11/2005
1Cyclic AMP-Dependent Protein Kinase RIalpha SubunitIBA
08/2005
1Phosphotransferases (Kinase)IBA
12/2004
1OligonucleotidesIBA
03/2004
1Biological ProductsIBA
03/2004
1Type I DNA Topoisomerases (Topoisomerase I)IBA
03/2003
1hydroxycamptothecinumIBA
03/2003
1GEM231IBA
03/2003
1homocamptothecinIBA
03/2003
18-chloro-cyclic adenosine monophosphateIBA
06/2002
1Transcription Factors (Transcription Factor)IBA
06/2002
1Hormones (Hormone)IBA
02/2002

Therapy/Procedure

4Therapeutics
08/2005 - 06/2002
1Chemoprevention
11/2005